Patents Examined by Maher M. Haddad
-
Patent number: 11643463Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.Type: GrantFiled: May 19, 2017Date of Patent: May 9, 2023Assignee: WUXI Biologics (Shanghai) Co., Ltd.Inventors: Zhuozhi Wang, Jing Li, Gennady Gololobov, Jianqing Xu
-
Patent number: 11643458Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.Type: GrantFiled: May 30, 2019Date of Patent: May 9, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Tatsuya Takahashi, Mai Yoshikawa, Sosuke Yoneda, Junji Onoda, Etsuo Nakamura, Tsuguo Miyauchi, Toshiyuki Asaki, Erika Kasai
-
Patent number: 11639377Abstract: The disclosure discloses a preparation of type I collagen-like fibers and a method for regulating and controlling the periodic length of fiber stripes thereof, belonging to the technical field of genetic engineering. The disclosure produces a three-segment chimeric collagen P-CL-P pattern by inserting a continuous Gly-Xaa-Yaa triplet collagen sequence in the middle based on the N- and C-terminal (GPP)n sequences. The self-assembly is driven by the interaction between the N- and C-terminal (GPP)n triple helixes to form banded fibers with periodic bright and dark stripes. According to the method of the disclosure, a fiber from a clean source, which can self-assemble to form periodic bright and dark stripes can be prepared, the structure of which is similar to type I collagen, the preparation process is simple, the collagen fiber with low cost can be produced on a large scale, and the method has broad application prospects in the field of biological materials.Type: GrantFiled: October 28, 2020Date of Patent: May 2, 2023Assignees: JIANGNAN UNIVERSITY, RUTGERS UNIVERSITYInventors: Fei Xu, Jinyuan Hu, Vikas Nanda, David I. Shreiber, Meng Zhang, Sonal Gahlawat
-
Patent number: 11639390Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.Type: GrantFiled: July 16, 2021Date of Patent: May 2, 2023Assignee: AbbVie Inc.Inventors: Jing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
-
Patent number: 11634490Abstract: Provided are anti-CD47 antibodies or fragments thereof that can bind to the extra cellular domain of the CD47 protein. The antibodies or fragments thereof can effectively block the interaction between human CD47 and its ligand SIRP alpha and enhance the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies or fragments do not induce in vitro hemagglutination and therefore can be suitably used as therapeutic agents with reduced off-target effects.Type: GrantFiled: June 14, 2019Date of Patent: April 25, 2023Assignee: Accurus Biosciences, Inc.Inventors: Haishan Lin, Yi Zhang
-
Patent number: 11623956Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.Type: GrantFiled: February 22, 2021Date of Patent: April 11, 2023Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
-
Patent number: 11623962Abstract: The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.Type: GrantFiled: August 17, 2020Date of Patent: April 11, 2023Assignee: SORRENTO THERAPEUTICS, INC.Inventor: Damien Bresson
-
Patent number: 11608378Abstract: Antibodies that bind to ???8 are provided.Type: GrantFiled: January 15, 2021Date of Patent: March 21, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Stephen L. Nishimura, Anthony Cormier, Saburo Ito, Jianlong Lou, James D. Marks, Yifan Cheng, Melody G. Campbell, Jody L. Baron
-
Patent number: 11596688Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.Type: GrantFiled: June 27, 2019Date of Patent: March 7, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Maria Rosario, Timothy L. Wyant, Brihad Abhyankar
-
Patent number: 11597765Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).Type: GrantFiled: June 21, 2021Date of Patent: March 7, 2023Assignees: VACCINEX, INC., The Sydney Children's Hospital NetworkInventors: Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
-
Patent number: 11591402Abstract: New antibodies and methods of use are described.Type: GrantFiled: January 22, 2021Date of Patent: February 28, 2023Assignee: The Regents of the University of CaliforniaInventors: Stephen L. Nishimura, Jianlong Lou, James D. Marks, Jody L. Baron, Yifan Cheng, Shenping Wu, Anthony Cormier, Naoki Takasaka
-
Patent number: 11590201Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders.Type: GrantFiled: September 5, 2019Date of Patent: February 28, 2023Assignee: ACCELERON PHARMA, INC.Inventors: Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
-
Patent number: 11560417Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.Type: GrantFiled: February 18, 2020Date of Patent: January 24, 2023Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: David Naor, Lora Eshkar-Sebban, Keren-Or Amar, Shmuel Cohen
-
Patent number: 11560433Abstract: Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.Type: GrantFiled: January 27, 2020Date of Patent: January 24, 2023Assignee: Albert Einstein College of MedicineInventors: Paul S. Frenette, Sandra Pinho, Qiaozhi Wei, Sung Kyun Lee
-
Patent number: 11542325Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.Type: GrantFiled: September 12, 2018Date of Patent: January 3, 2023Assignee: Amgen Inc.Inventors: Huiquan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 11505603Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.Type: GrantFiled: February 28, 2019Date of Patent: November 22, 2022Assignee: YUHAN CORPORATIONInventors: Kwang-Hoon Lee, June Hyung Lee, Na Rae Lee, Eunjeong Jeong, Young Bong Park, Nakho Chang, Eun-Jung Lee, Ki Hong Kim, Sunghyun Choi, Byung Hyun Choi, Ju Young Park, Moo Young Song, Jong-Seo Lee, Kyu-Tae Kim, Bong-Kook Ko
-
Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
Patent number: 11492406Abstract: Methods and compositions comprising integrin ?8 antibodies are provided.Type: GrantFiled: February 14, 2020Date of Patent: November 8, 2022Assignee: The Regents of the University of CaliforniaInventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson -
Patent number: 11485786Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.Type: GrantFiled: August 15, 2019Date of Patent: November 1, 2022Assignee: Merck Patent GmbHInventors: Ilhan Celik, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
-
Patent number: 11479610Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.Type: GrantFiled: December 22, 2021Date of Patent: October 25, 2022Assignee: Cantargia ABInventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
-
Patent number: 11472882Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.Type: GrantFiled: February 1, 2019Date of Patent: October 18, 2022Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Rudi Bao, Haiqing Hua, Suxia Liu, Fujun Zhang, Ting Wang